France-based biologics company Valneva will be advancing toward U.S. Food and Drug Administration accelerated approval of its specialty vaccine, VLA1553. The single-shot chikungunya vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease in a published analysis of Phase III results.